1. Akileswaran C et al. (2005). Lessons learned from use of highly active antiretroviral therapy in Africa. Clinical Infectious Diseases; 41:376-385.
2. American Public Health Association (June 2004). Adherence to HIV treatment regimens: recommendations for best practices. Available at: www.apha.org/ppp/hiv.
3. Bennet S, Boerma JT, Brugha R (2006). Scaling up of HIV/AIDS evaluation. Lancet, 367:79-82.
4. Carrieri MP et al. (2003). Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antiviral Therapy, 8(6):585-94.
5. Chesney MA (2000). Factors affecting adherence to antiretroviral therapy. Clinical Infectious Diseases, 30 (Suppl 2):S171-176.
6. Coetzee D et al. (2004). Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS, 18(Suppl 3):S27-31.
7. DiMatteo MR (2004). Variations in patients' adherence to medical recommendations. A quantitative review of 50 years of research. Medical Care, 42:200-209.
8. Farmer F et al. (2001). Community-based approaches to HIV treatment in resource-poor settings. Lancet, 358:404-409.
9. G8 Gleneagles Summit. Chair's summary, 8h July 2005. Available at: http://www.g8.gov.uk/
10. Gill CJ et al. (2005). No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS, 19:1243-1249.
11. Hardon A, Hodgkin C, Fresle D. How to investigate the use of medicines by consumers. Geneva, World Health Organization, 2004.
12. Ivers LC, Kendrick D, Doucette K (2005). Efficacy of antiretroviral therapy programmes in resource-poor settings: a meta-analysis of the published literature. Clinical Infectious Diseases, 41:217-224.
13. Jaffar S et al. (2005). Antiretroviral treatment in resource-poor settings: public health research priorities. Tropical Medicine and International Health, 2005; 10:295-299.
14. Kent DM et al. (2003). Suitable monitoring approaches to antiretroviral therapy in resource- poor settings: setting the research agenda. Clinical Infectious Diseases, 37 (Suppl l):S13-24.
15. Koenig SP, Léandre F, Farmer PE (2004). Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS, 18 (Suppl 3):S21-25.
16. Laurent C et al. (2002). The Senegalese Government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS, 16:1363-1370.
17. Orrell C et al. (2003). Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS, 17:1369-1375.
18. Oyugi JH et al. (2004). Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in resource-limited setting. Journal of Acquired Immune Deficiency Syndrome, 36:1100-1102.
19. Paterson DL et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 2000;122:21-30.
20. Spire B et al. (2002). Adherence to highly active antiretroviral therapy (HAART) in HIV- infected patients: from a predictive to a dynamic approach. Social Science and Medicine, 54(10):1481-96.
21. UNAIDS. 2006 Report on the global AIDS epidemic. Geneva, United Nations Joint Programme on AIDS, 2006.
22. Vitolins MZ et al. (2000). Measuring adherence to behavioral and medical interventions. Controlled Clinical Trials 2000; 21:188S-194S.
23. Weiser S et al. (2003). Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal of Acquired Immune Deficiency Syndromes, 34:281-288.
24. WHO. Adherence to HIV treatment. Geneva, World Health Organization, 2004.
25. WHO/UNAIDS. Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond. Geneva, World Health Organization/United Nations Joint Programme on AIDS, 2006.